LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis
In chronic stable HFrEF, lower baseline LDL-C (< 100 mg/dL) is associated with higher all-cause mortality but not with ischemic events. The net benefit of lipid-lowering therapy in ischemic HFrEF remains uncertain and merits validation in phenotype-specific randomized trials.
Authors
- Wenqing Zhou (ORCID: https://orcid.org/0000-0002-8800-3745)
- Qi Wang (ORCID: https://orcid.org/0000-0003-3694-5826)
- Kai Hu (ORCID: https://orcid.org/0000-0003-2673-6684)
- Kangyu Chen (ORCID: https://orcid.org/0000-0002-7095-6767)
- Zhiquan Liu (ORCID: https://orcid.org/0000-0003-4917-7686)
- Hao Su (ORCID: https://orcid.org/0000-0003-0519-6471)
- Ji Yan (ORCID: https://orcid.org/0000-0002-2558-7210)
- Guohong Wu
Institutions
- University of Science and Technology of China (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1038/s41598-025-24832-9
- Primary Topic
- Cardiovascular Function and Risk Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00